Clinical Report: Approximately Four Million Medicare Recipients Qualified for the 2023 Medicare GLP-1 Bridge Program
Overview
The Medicare GLP-1 Bridge Program, starting July 2026, may cover nearly four million beneficiaries for GLP-1 medications aimed at weight management. Eligibility criteria are defined, focusing on specific BMI and comorbid conditions.
Background
Obesity is a significant public health concern, affecting a substantial portion of the Medicare population. The introduction of the Medicare GLP-1 Bridge Program aims to provide access to GLP-1 medications for weight management, addressing the needs of beneficiaries who do not qualify for existing Part D coverage.
Data Highlights
In 2023, an estimated 3.8 million Medicare beneficiaries met the eligibility criteria for the Medicare GLP-1 Bridge Program.
Key Findings
The Medicare GLP-1 Bridge will cover GLP-1 medications for weight management at a $50 monthly copayment.
Eligibility is limited to beneficiaries with specific BMI thresholds and certain comorbid conditions.
More than 13 million Medicare beneficiaries met the BMI criteria for obesity or overweight in 2023.
Approximately 9.7 million Medicare Part D enrollees met the clinical criteria for the Bridge in 2023.
Beneficiaries must not have filled a GLP-1 prescription under Part D in 2026 to qualify for the Bridge.
Clinical Implications
Healthcare providers should be aware of the eligibility criteria for the Medicare GLP-1 Bridge Program to appropriately guide patients seeking weight management options.
Conclusion
The Medicare GLP-1 Bridge Program has specific eligibility criteria that healthcare providers must navigate.
